ReviewHead and neck pathology2025
Erdheim-Chester Disease of the Jaws: A Case Report and Review of the Literature.
Review in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Erdheim-Chester disease presenting as abdominal cocoon syndrome.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytic disease characterized by xanthogranulomatous infiltration of multiple organ systems by histiocytes that are negative for langerin (CD207) and CD1a. BRAF V600E mutation is present in 54% of the cases. The disease most commonly affects males in their 5th and 7th decades and bone is involved in 96% of cases although there have been only 8 reported cases of ECD involving the jaws. This is a case of ECD in a 57-year-old male who presented for extractions and implant placement. Radiographic examination revealed extensive bone loss in the posterior mandible and maxilla. Biopsy of the lytic lesions showed infiltration by epithelioid histiocytes with Touton-type multinucleated giant cells that were positive for BRAF and CD163 and negative for CD1a, consistent with the patient’s known history of ECD. He had been diagnosed with ECD 8 years prior with involvement of the long bones and subsequently the skin. The patient started vemurafenib treatment in July 2020 for progressive disease and his disease remains stable. Of the 8 previously reported cases involving the jaws, the median age at diagnosis was 35 years and both genders were equally affected. Reports describe multiple, often bilateral, mixed lytic-sclerotic lesions. Both the mandible and maxilla were affected in 75% of the cases and the mandible alone was involved in one case. None of the cases affected the maxilla alone. Current management includes the use of BRAF inhibitors and MEK inhibitors in the presence of BRAF mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.